Latest News for: Btc design center

Edit

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in ...

The Eagle-Tribune 08 Dec 2023
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified biliary tract cancers (BTC), and two Fast Track designations for zanidatamab.
Edit

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers ...

The Huntsville Item 30 Nov 2023
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab in patients with previously treated HER2 gene-amplified biliary tract cancers (BTC), and two Fast Track designations for zanidatamab.
Edit

Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

Longview News-Journal 07 Nov 2023
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified biliary tract cancers (BTC), and two Fast Track designations for zanidatamab.
Edit

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel ...

Eagle-Tribune 19 Jan 2023
in patients with BTC ... CTX-009 Phase 2 BTC Study Design. The Phase 2 study is being conducted at four leading medical centers in Korea and has a Simon Two-Stage adaptive design ... CTX-009 Phase 2/3 BTC Study Design.
  • 1
×